1013 related articles for article (PubMed ID: 28716211)
1. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
2. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
Peyvandi F; Miri S; Garagiola I
Front Immunol; 2020; 11():591878. PubMed ID: 33552050
[TBL] [Abstract][Full Text] [Related]
3. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
5. Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
Gringeri A; Ofosu FA; Grancha S; Oldenburg J; Ewing NP; Federici AB
Haemophilia; 2012 May; 18(3):469-75. PubMed ID: 21943193
[TBL] [Abstract][Full Text] [Related]
6. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.
Gangadharan B; Ing M; Delignat S; Peyron I; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
Haematologica; 2017 Feb; 102(2):271-281. PubMed ID: 27758819
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
8. The role of VWF in the immunogenicity of FVIII.
Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
[TBL] [Abstract][Full Text] [Related]
9. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
11. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
[TBL] [Abstract][Full Text] [Related]
12. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
13. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
15. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
Berntorp E
Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
[TBL] [Abstract][Full Text] [Related]
17. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.
Kallas A; Talpsep T
Haemophilia; 2001 Jul; 7(4):375-80. PubMed ID: 11442642
[TBL] [Abstract][Full Text] [Related]
18. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
Berntorp E
Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
[TBL] [Abstract][Full Text] [Related]
19. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
20. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Oldenburg J; Lacroix-Desmazes S; Lillicrap D
Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
